Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of diabetic nephropathy in Chinese patients with newly diagnosed type 2 diabetes: A cross-sectional study

Diabetes and Vascular Disease Research

Volumn 13, Issue 2, 2016, Pages 127-136

  Zheng, Tianpeng ^a   Liu, Yihong ^b   Qin, Shenghua ^a   Liu, Hongbo ^a   Zhang, Xiaoxi ^a   Zhao, Hailu ^a  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b Diabetic Centre of Control and Prevention People's Liberation Army 520 Hospital   (China)

Author keywords

diabetic nephropathy; DPP4 activity; inflammation; insulin resistance; oxidative stress

Indexed keywords

3 NITROTYROSINE; 8 ISOPROSTAGLANDIN F2 ALPHA; C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV; HEMOGLOBIN A1C; INTERLEUKIN 6; SOMATOMEDIN B RECEPTOR; BIOLOGICAL MARKER; DPP4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; ALBUMINURIA; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PREVALENCE; RISK FACTOR;

ADULT; AGED; ALBUMINURIA; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL PEPTIDASE 4; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 84958154465     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164115615356     Document Type: Article

References (31)

1. Ritz E, Orth SR,. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-1133.
2. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
3. Matteucci E, Giampietro O,. Dipeptidyl peptidase-4 (cd26): knowing the function before inhibiting the enzyme. Curr Med Chem 2009; 16: 2943-2951.
4. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60: 1917-1925.
5. Zheng T, Gao Y, Baskota A, et al. Increased plasma dpp4 activity is predictive of prediabetes and type 2 diabetes onset in Chinese over a four-year period: result from the china national diabetes and metabolic disorders study. J Clin Endocrinol Metab 2014; 99: E2330-E2334.
6. Sell H, Blüher M, Klöting N, et al. Adipose dipeptidyl peptidase-4 and obesity correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 2013; 36: 4083-4090.
7. Zheng T, Baskota A, Gao Y, et al. Increased plasma dipeptidyl peptidase 4 activities predict new-onset microalbuminuria in association with its proinflammatory effects in Chinese without diabetes: a four-year prospective study. Nephrol Dial Transplant 2015; 30: 460-466.
8. Zheng T, Chen T, Liu Y, et al. Increased plasma dpp4 activity predicts new-onset hypertension in Chinese over a 4-year period: possible associations with inflammation and oxidative stress. J Hum Hypertens 2015; 29: 424-429.
9. Ikushima H, Munakata Y, Iwata S, et al. Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cell Immunol 2002; 215: 106-110.
10. Ishibashi Y, Matsui T, Maeda S, et al. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol 2013; 12: 125.
11. Haluzík M, Frolík J, Rychlík I,. Renal effects of dpp-4 inhibitors: a focus on microalbuminuria. Int J Endocrinol 2013; 2013: 895102.
12. Alberti KGMM, Zimmet PZ,. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
13. Molitch ME, Steffes M, Sun W, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010; 33: 1536-1543.
14. Stevens PE, Levin A,. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158: 825-830.
15. Ma Y, Zuo L, Chen J, et al. Improved GFR estimation by combined creatinine and cystatin C measurements. Kidney Int 2007; 72: 1535-1542.
16. Hui E, Yeung C-Y, Lee PC, et al. Elevated circulating pigment epithelium-derived factor predicts the progression of diabetic nephropathy in patients with type 2 diabetes. J Clin Endocrinol Metab 2014; 99: E2169-E2177.
17. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36: S11-S66.
18. Luepker R, Evans A, McKeigue P, et al. Cardiovascular survey methods. Geneva: World Health Organization, 2004.
19. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in china. N Engl J Med 2010; 362: 1090-1101.
20. Forbes JM, Cooper ME,. Mechanisms of diabetic complications. Physiol Rev 2013; 93: 137-188.
21. Ryskjær J, Deacon CF, Carr RD, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbA1c levels, but is not acutely affected by food intake. Eur J Endocrinol 2006; 155: 485-493.
22. Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005; 48: 1168-1172.
23. Kirino Y, Sei M, Kawazoe K, et al. Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people. Endocr J 2011; 59: 949-953.
24. Welsh GI, Hale LJ, Eremina V, et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 2010; 12: 329-340.
25. Jeyaratnaganthan N, Højlund K, Kroustrup JP, et al. Circulating levels of insulin-like growth factor-ii/mannose-6-phosphate receptor in obesity and type 2 diabetes. Growth Horm IGF Res 2010; 20: 185-191.
26. Cordero OJ, Salgado FJ, Viñuela JE, et al. Interleukin-12 enhances CD23 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiology 1997; 197: 522-533.
27. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790.
28. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897.
29. Mentlein R,. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
30. Leicht S, Shipkova M, Klett C, et al. CD26/dipeptidyl peptidase IV: a comparative study of healthy persons and kidney transplant recipients before and early after transplantation. Clin Biochem 2013; 46: 1383-1388.
31. Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 2014; 85: 579-589.